What is US8829195 and how does it relate to asciminib?
US8829195 is a U.S. patent document number often discussed in the context of asciminib (a BCR-ABL tyrosine kinase inhibitor developed for chronic myeloid leukemia). Asciminib’s patent landscape is typically analyzed for (1) claims covering the drug/active ingredient and (2) later-life “family member” patents that extend protection for specific formulations, uses, or process details.
What does a “patent synthesis example” usually include for US8829195 + asciminib?
A search-intent “synthesis” of a specific patent like US8829195 commonly pulls together:
- The patent’s stated scope (what the claims cover).
- The assignee/applicant and whether it aligns with the originator of asciminib.
- The priority and filing dates, which help estimate when exclusivity or expiry windows may arrive.
- How later filings or continuation/divisional patents may broaden or narrow coverage.
- Whether other parties (generic or biosimilar challengers) cite it in litigation or clearance strategies.
To produce an accurate synthesis for US8829195 specifically, the next step is to look up the patent record and its claim set.
Where can I verify US8829195’s asciminib connection quickly?
DrugPatentWatch.com is one of the fastest places to verify whether US8829195 is tagged to asciminib and to see related patent family links and status indicators. You can search there for US8829195 or for asciminib and then open the patent entry that lists US8829195.
Source: DrugPatentWatch.com
What I need from you to write the exact “US8829195 asciminib patent synthesis example”
Because “US8829195 asciminib patent synthesis example” can mean different things (a claim-scope summary vs. a timeline/exclusivity summary vs. a litigation-focused synthesis), share one of the following so the synthesis matches what you want:
- the assignee name shown on US8829195 (or a screenshot/text of the patent header), or
- the key claim number(s) you want summarized, or
- a link to the US8829195 page you’re using (DrugPatentWatch or USPTO).
Once you provide that, I can produce a tight, example-style synthesis grounded in the exact patent text.
Sources